{
    "Trade/Device Name(s)": [
        "VITROS Immunodiagnostic Products CEA Reagent Pack",
        "VITROS CEA Reagent Pack"
    ],
    "Submitter Information": "Ortho-Clinical Diagnostics Inc.",
    "510(k) Number": "K231517",
    "Predicate Device Reference 510(k) Number(s)": [
        "K041322"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHX"
    ],
    "Summary Letter Date": "August 23, 2023",
    "Summary Letter Received Date": "May 25, 2023",
    "Submission Date": "May 23, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Carcinoembryonic antigen (CEA)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VITROS 5600 Integrated System"
    ],
    "Method(s)/Technology(ies)": [
        "Immunometric immunoassay",
        "Luminescent detection"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for VITROS Immunodiagnostic Products CEA Reagent Pack for quantifying CEA in serum/plasma on the VITROS 5600 Integrated System",
    "Indications for Use Summary": "Quantitative measurement of carcinoembryonic antigen (CEA) concentration in human serum and plasma (EDTA or heparin) to aid in the prognosis and management of cancer patients with observed changes in CEA concentrations",
    "fda_folder": "Immunology"
}